Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
ETX Daily Up on MSN48m
Social interaction, a bulwark against dementia?
In Alzheimer's & Dementia: The Journal of the Alzheimer's Association, researchers at Rush University suggest that maintaining a healthy brain depends on regular social interaction.